Ontario

Ministry of Health

Drugs and Devices Division

Executive Officer Notice: Updates to the Ontario Guidelines for Drug Submission and Evaluation

The purpose of this notice is to provide information regarding interim measures to respond to scenarios that may arise due to COVID-19.

Effective immediately, the Drugs and Devices Division (DDD) will accept e-mail submissions instead of electronic copies on USB, CD or DVD. This applies to all product submissions (including but not limited to Single Source Drug Product submissions, Multiple Source Drug Product submissions, Valved Holding Chamber submissions, Diabetic Testing Agent submissions, and Nutrition Product submissions).

Please send the submissions to the DDD's email mailbox DrugSubmissions.MOH@ontario.ca

Manufacturers must continue to make submissions to the Drugs and Devices Division to have their products considered by the Executive Officer for listing and funding, in accordance with Ontario Regulation 201/96 under the *Ontario Drug Benefit Act* and Regulation 935 under the *Drug Interchangeability and Dispensing Fee Act.*

For a multiple source drug product to be considered for inclusion in a monthly review cycle for listing in a future Formulary Update, the submission must be received by the monthly submission deadline. Please refer to the monthly submission deadline date on the ministry website.

For more information, please visit the ministry's website at: Drug Submissions